Sinovac Biotech Hit with Nasdaq Warning on Delayed 2025 Interim Filing
“Sinovac Biotech has received a fresh Nasdaq non-compliance notice for failing to file its 2025 half-year financial report on time, compounding earlier delisting risks. The company plans to address the issue at an upcoming hearing, aiming to preserve its listing amid ongoing internal challenges and auditor transitions.” Nasdaq’s Latest Non-Compliance Notice Sinovac Biotech, the Chinese … Read more